@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sct: <http://snomed.info/id/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<https://www.vision-zero-oncology.de/fhir/ResearchStudy/ExampleStudyRAAINBOW> a fhir:ResearchStudy;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value "ExampleStudyRAAINBOW"];
  fhir:Resource.meta [
     fhir:Meta.profile [
       fhir:value "https://www.vision-zero-oncology.de/fhir/StructureDefinition/clinical-study";
       fhir:index 0;
       fhir:link <https://www.vision-zero-oncology.de/fhir/StructureDefinition/clinical-study>
     ]
  ];
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value "generated" ];
     fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: ResearchStudy</b><a name=\"ExampleStudyRAAINBOW\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ResearchStudy &quot;ExampleStudyRAAINBOW&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-clinical-study.html\">Clinical Study</a></p></div><p><b>identifier</b>: id: NCT03240627</p><p><b>title</b>: Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.</p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: Treatment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-prim-purp-type.html\">ResearchStudyPrimaryPurposeType</a>#treatment)</span></p><p><b>phase</b>: Phase 2/Phase 3 <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-phase.html\">ResearchStudyPhase</a>#phase-2-phase-3)</span></p><p><b>category</b>: Interventional Study <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C98388)</span>, Randomized Controlled Clinical Trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C46079)</span>, Double Blind Study <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C15228)</span>, Unequal Randomization <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C142743)</span></p><p><b>focus</b>: Pharmacologic Substance <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C1909)</span></p><p><b>condition</b>: Alopecia areata (disorder) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#68225006)</span></p><p><b>location</b>: Germany <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#DE)</span>, France <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#FR)</span></p><p><b>period</b>: 2018-03-01 --&gt; 2022-03-17</p><p><b>principalInvestigator</b>: <a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Practitioner/example\">Practitioner/example</a></p><p><b>site</b>: </p><ul><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Charite-dermatology\">Organization/Charite-dermatology</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Sabouraud-Center\">Organization/Sabouraud-Center</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Diagnostic-consulting-center-XXIV-Sofia\">Organization/Diagnostic-consulting-center-XXIV-Sofia</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/SC-Centrul-Medical-Sana-SRL\">Organization/SC-Centrul-Medical-Sana-SRL</a></li></ul><blockquote><p><b>arm</b></p><p><b>name</b>: Experimental: LH-8 cutaneous solution</p><p><b>type</b>: Investigational Arm <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C174266)</span></p><p><b>description</b>: LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo Comparator: Placebo cutaneous solution</p><p><b>type</b>: Control Arm <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C174226)</span></p><p><b>description</b>: Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation.</p><p><b>type</b>: Primary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#primary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Adverse events [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation).</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/4.0.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote></div>"
  ];
  fhir:ResearchStudy.identifier [
     fhir:index 0;
     fhir:Identifier.system [ fhir:value "http://clinicaltrials.gov" ];
     fhir:Identifier.value [ fhir:value "NCT03240627" ]
  ];
  fhir:ResearchStudy.title [ fhir:value "Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata."];
  fhir:ResearchStudy.status [ fhir:value "completed"];
  fhir:ResearchStudy.primaryPurposeType [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type" ];
       fhir:Coding.code [ fhir:value "treatment" ]
     ]
  ];
  fhir:ResearchStudy.phase [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-phase" ];
       fhir:Coding.code [ fhir:value "phase-2-phase-3" ];
       fhir:Coding.display [ fhir:value "Phase 2/Phase 3" ]
     ]
  ];
  fhir:ResearchStudy.category [
     fhir:index 0;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" ];
       fhir:Coding.code [ fhir:value "C98388" ];
       fhir:Coding.display [ fhir:value "Interventional Study" ]
     ]
  ], [
     fhir:index 1;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" ];
       fhir:Coding.code [ fhir:value "C46079" ];
       fhir:Coding.display [ fhir:value "Randomized Controlled Clinical Trial" ]
     ]
  ], [
     fhir:index 2;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" ];
       fhir:Coding.code [ fhir:value "C15228" ];
       fhir:Coding.display [ fhir:value "Double Blind Study" ]
     ]
  ], [
     fhir:index 3;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" ];
       fhir:Coding.code [ fhir:value "C142743" ];
       fhir:Coding.display [ fhir:value "Unequal Randomization" ]
     ]
  ];
  fhir:ResearchStudy.focus [
     fhir:index 0;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" ];
       fhir:Coding.code [ fhir:value "C1909" ];
       fhir:Coding.display [ fhir:value "Pharmacologic Substance" ]
     ]
  ];
  fhir:ResearchStudy.condition [
     fhir:index 0;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       a sct:68225006;
       fhir:Coding.system [ fhir:value "http://snomed.info/sct" ];
       fhir:Coding.code [ fhir:value "68225006" ];
       fhir:Coding.display [ fhir:value "Alopecia areata (disorder)" ]
     ]
  ];
  fhir:ResearchStudy.location [
     fhir:index 0;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "urn:iso:std:iso:3166" ];
       fhir:Coding.code [ fhir:value "DE" ];
       fhir:Coding.display [ fhir:value "Germany" ]
     ]
  ], [
     fhir:index 1;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "urn:iso:std:iso:3166" ];
       fhir:Coding.code [ fhir:value "FR" ];
       fhir:Coding.display [ fhir:value "France" ]
     ]
  ];
  fhir:ResearchStudy.period [
     fhir:Period.start [ fhir:value "2018-03-01"^^xsd:date ];
     fhir:Period.end [ fhir:value "2022-03-17"^^xsd:date ]
  ];
  fhir:ResearchStudy.principalInvestigator [
     fhir:link <https://www.vision-zero-oncology.de/fhir/Practitioner/example>;
     fhir:Reference.reference [ fhir:value "Practitioner/example" ]
  ];
  fhir:ResearchStudy.site [
     fhir:index 0;
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/Charite-dermatology>;
     fhir:Reference.reference [ fhir:value "Organization/Charite-dermatology" ]
  ], [
     fhir:index 1;
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/Sabouraud-Center>;
     fhir:Reference.reference [ fhir:value "Organization/Sabouraud-Center" ]
  ], [
     fhir:index 2;
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/Diagnostic-consulting-center-XXIV-Sofia>;
     fhir:Reference.reference [ fhir:value "Organization/Diagnostic-consulting-center-XXIV-Sofia" ]
  ], [
     fhir:index 3;
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/SC-Centrul-Medical-Sana-SRL>;
     fhir:Reference.reference [ fhir:value "Organization/SC-Centrul-Medical-Sana-SRL" ]
  ];
  fhir:ResearchStudy.arm [
     fhir:index 0;
     fhir:ResearchStudy.arm.name [ fhir:value "Experimental: LH-8 cutaneous solution" ];
     fhir:ResearchStudy.arm.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" ];
         fhir:Coding.code [ fhir:value "C174266" ];
         fhir:Coding.display [ fhir:value "Investigational Arm" ]
       ]
     ];
     fhir:ResearchStudy.arm.description [ fhir:value "LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp" ]
  ], [
     fhir:index 1;
     fhir:ResearchStudy.arm.name [ fhir:value "Placebo Comparator: Placebo cutaneous solution" ];
     fhir:ResearchStudy.arm.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" ];
         fhir:Coding.code [ fhir:value "C174226" ];
         fhir:Coding.display [ fhir:value "Control Arm" ]
       ]
     ];
     fhir:ResearchStudy.arm.description [ fhir:value "Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp" ]
  ];
  fhir:ResearchStudy.objective [
     fhir:index 0;
     fhir:ResearchStudy.objective.name [ fhir:value "Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation." ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "primary" ]
       ]
     ]
  ], [
     fhir:index 1;
     fhir:ResearchStudy.objective.name [ fhir:value "Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 2;
     fhir:ResearchStudy.objective.name [ fhir:value "Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 3;
     fhir:ResearchStudy.objective.name [ fhir:value "Adverse events [ Time Frame: 48 weeks ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 4;
     fhir:ResearchStudy.objective.name [ fhir:value "General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 5;
     fhir:ResearchStudy.objective.name [ fhir:value "Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 6;
     fhir:ResearchStudy.objective.name [ fhir:value "Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 7;
     fhir:ResearchStudy.objective.name [ fhir:value "Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 8;
     fhir:ResearchStudy.objective.name [ fhir:value "Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 9;
     fhir:ResearchStudy.objective.name [ fhir:value "Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation)." ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 10;
     fhir:ResearchStudy.objective.name [ fhir:value "Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 11;
     fhir:ResearchStudy.objective.name [ fhir:value "Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 12;
     fhir:ResearchStudy.objective.name [ fhir:value "Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 13;
     fhir:ResearchStudy.objective.name [ fhir:value "Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ], [
     fhir:index 14;
     fhir:ResearchStudy.objective.name [ fhir:value "Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]" ];
     fhir:ResearchStudy.objective.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/research-study-objective-type" ];
         fhir:Coding.code [ fhir:value "secondary" ]
       ]
     ]
  ] .

# - ontology header ------------------------------------------------------------

<https://www.vision-zero-oncology.de/fhir/ResearchStudy/ExampleStudyRAAINBOW.ttl> a owl:Ontology;
  owl:imports fhir:fhir.ttl .

# -------------------------------------------------------------------------------------

